IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v15y2024i1d10.1038_s41467-024-48555-z.html
   My bibliography  Save this article

Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus

Author

Listed:
  • Colleen Furey

    (University of Pennsylvania)

  • Gabrielle Scher

    (University of Pennsylvania)

  • Naiqing Ye

    (University of Pennsylvania)

  • Lisa Kercher

    (St. Jude Children’s Research Hospital)

  • Jennifer DeBeauchamp

    (St. Jude Children’s Research Hospital)

  • Jeri Carol Crumpton

    (St. Jude Children’s Research Hospital)

  • Trushar Jeevan

    (St. Jude Children’s Research Hospital)

  • Christopher Patton

    (St. Jude Children’s Research Hospital
    University of Tennessee Health Science Center)

  • John Franks

    (St. Jude Children’s Research Hospital)

  • Adam Rubrum

    (St. Jude Children’s Research Hospital)

  • Mohamad-Gabriel Alameh

    (University of Pennsylvania
    University of Pennsylvania)

  • Steven H. Y. Fan

    (Acuitas Therapeutics)

  • Anthony T. Phan

    (University of Pennsylvania)

  • Christopher A. Hunter

    (University of Pennsylvania)

  • Richard J. Webby

    (St. Jude Children’s Research Hospital)

  • Drew Weissman

    (University of Pennsylvania
    University of Pennsylvania)

  • Scott E. Hensley

    (University of Pennsylvania)

Abstract

mRNA lipid nanoparticle (LNP) vaccines would be useful during an influenza virus pandemic since they can be produced rapidly and do not require the generation of egg-adapted vaccine seed stocks. Highly pathogenic avian influenza viruses from H5 clade 2.3.4.4b are circulating at unprecedently high levels in wild and domestic birds and have the potential to adapt to humans. Here, we generate an mRNA lipid nanoparticle (LNP) vaccine encoding the hemagglutinin (HA) glycoprotein from a clade 2.3.4.4b H5 isolate. The H5 mRNA-LNP vaccine elicits strong T cell and antibody responses in female mice, including neutralizing antibodies and broadly-reactive anti-HA stalk antibodies. The H5 mRNA-LNP vaccine elicits antibodies at similar levels compared to whole inactivated vaccines in female mice with and without prior H1N1 exposures. Finally, we find that the H5 mRNA-LNP vaccine is immunogenic in male ferrets and prevents morbidity and mortality of animals following 2.3.4.4b H5N1 challenge. Together, our data demonstrate that a monovalent mRNA-LNP vaccine expressing 2.3.4.4b H5 is immunogenic and protective in pre-clinical animal models.

Suggested Citation

  • Colleen Furey & Gabrielle Scher & Naiqing Ye & Lisa Kercher & Jennifer DeBeauchamp & Jeri Carol Crumpton & Trushar Jeevan & Christopher Patton & John Franks & Adam Rubrum & Mohamad-Gabriel Alameh & St, 2024. "Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus," Nature Communications, Nature, vol. 15(1), pages 1-12, December.
    • Handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48555-z
    DOI: 10.1038/s41467-024-48555-z
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-024-48555-z
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-024-48555-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Norbert Pardi & Kaela Parkhouse & Ericka Kirkpatrick & Meagan McMahon & Seth J. Zost & Barbara L. Mui & Ying K. Tam & Katalin Karikó & Christopher J. Barbosa & Thomas D. Madden & Michael J. Hope & Flo, 2018. "Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies," Nature Communications, Nature, vol. 9(1), pages 1-12, December.
    2. Sigrid Gouma & Kangchon Kim & Madison E. Weirick & Megan E. Gumina & Angela Branche & David J. Topham & Emily T. Martin & Arnold S. Monto & Sarah Cobey & Scott E. Hensley, 2020. "Middle-aged individuals may be in a perpetual state of H3N2 influenza virus susceptibility," Nature Communications, Nature, vol. 11(1), pages 1-8, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Simon P. J. Jong & Zandra C. Felix Garza & Joseph C. Gibson & Sarah Leeuwen & Robert P. Vries & Geert-Jan Boons & Marliek Hoesel & Karen Haan & Laura E. Groeningen & Katina D. Hulme & Hugo D. G. Willi, 2024. "Determinants of epidemic size and the impacts of lulls in seasonal influenza virus circulation," Nature Communications, Nature, vol. 15(1), pages 1-11, December.
    2. Vijaykrishna Dhanasekaran & Sheena Sullivan & Kimberly M. Edwards & Ruopeng Xie & Arseniy Khvorov & Sophie A. Valkenburg & Benjamin J. Cowling & Ian G. Barr, 2022. "Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination," Nature Communications, Nature, vol. 13(1), pages 1-11, December.
    3. Tim K. Tsang & Ranawaka A. P. M. Perera & Vicky J. Fang & Jessica Y. Wong & Eunice Y. Shiu & Hau Chi So & Dennis K. M. Ip & J. S. Malik Peiris & Gabriel M. Leung & Benjamin J. Cowling & Simon Caucheme, 2022. "Reconstructing antibody dynamics to estimate the risk of influenza virus infection," Nature Communications, Nature, vol. 13(1), pages 1-8, December.
    4. Rebecca A. Leonard & Kaitlyn N. Burke & Rachel L. Spreng & Andrew N. Macintyre & Ying Tam & Mohamad-Gabriel Alameh & Drew Weissman & Nicholas S. Heaton, 2024. "Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA," Nature Communications, Nature, vol. 15(1), pages 1-15, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-48555-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.